Obecabtagene autoleucel (CARLYSLE)

October 5, 2026: Autolus Therapeutics plc (NASDAQ: AUTL) announced publication of an abstract for ACR Convergence 2026, where updated Phase 1 CARLYSLE data for obecabtagene autoleucel (obe-cel), a CD19 CAR-T therapy, in severe refractory systemic lupus erythematosus (srSLE) will be presented.

The poster presentation is scheduled for November 10, 2026, 10:30 AM–12:30 PM ET at the American College of Rheumatology meeting in Orlando, Florida. The abstract is titled “Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE Study” (Abstract 2216).

According to the release, the update will include safety and efficacy results from the ongoing Phase 1 CARLYSLE study, with up to 20 months of follow-up in adult patients and at least 3 months of follow-up in adolescent patients. No new trial results were disclosed in the release itself.